Drug maker urges group to lobby FDA on testosterone for women.
作者信息
Moynihan Ray
出版信息
BMJ. 2004 Nov 27;329(7477):1255. doi: 10.1136/bmj.329.7477.1255.
Abstract
摘要
相似文献
1
Drug maker urges group to lobby FDA on testosterone for women.制药商敦促该组织就女性用睾酮向美国食品药品监督管理局进行游说。
BMJ. 2004 Nov 27;329(7477):1255. doi: 10.1136/bmj.329.7477.1255.
2
The other side: failure in fair and balanced reporting.另一方面：公正平衡报道的失败。
J Sex Med. 2005 Jul;2(4):583-4.
3
Intrinsa fails to impress FDA advisory panel.
Int J Impot Res. 2005 May-Jun;17(3):283-4. doi: 10.1038/sj.ijir.3901308.
4
Commentary on androgen deficiency in women and the FDA advisory board's recent decision to request more safety data.关于女性雄激素缺乏以及美国食品药品监督管理局咨询委员会近期要求获取更多安全数据的决定的评论
Int J Impot Res. 2005 Jul-Aug;17(4):375-6. doi: 10.1038/sj.ijir.3901332.
5
FDA panel rejects testosterone patch for women on safety grounds.美国食品药品监督管理局专家小组基于安全理由否决了女性用睾酮贴片。
BMJ. 2004 Dec 11;329(7479):1363. doi: 10.1136/bmj.329.7479.1363.
6
The testosterone patch for women.女性用睾酮贴片。
Int J Impot Res. 2005 Sep-Oct;17(5):465-6. doi: 10.1038/sj.ijir.3901375.
7
Drug for low sexual desire carries significant harms, FDA advisers find.
BMJ. 2010 Jul 7;341:c3339. doi: 10.1136/bmj.c3339.
8
FDA committee recommends approval for "female Viagra".
BMJ. 2015 Jun 5;350:h3097. doi: 10.1136/bmj.h3097.
9
Implementing a successful clinical development program for female sexual dysfunctions (aka how to navigate a regulatory minefield).为女性性功能障碍实施一个成功的临床开发项目（即如何在监管雷区中前行）。
Maturitas. 2011 Jun;69(2):97-8. doi: 10.1016/j.maturitas.2011.03.014. Epub 2011 Apr 15.
10
Clinical pharmacology aspects of sex-related drug products.性相关药物产品的临床药理学方面。
Clin Pharmacol Ther. 2011 Jan;89(1):26-8. doi: 10.1038/clpt.2010.270.
本文引用的文献
1
Revised definitions of women's sexual dysfunction.女性性功能障碍的修订定义。
J Sex Med. 2004 Jul;1(1):40-8. doi: 10.1111/j.1743-6109.2004.10107.x.
Zotero 插件